Stock Information
Latest News
News Functions
Additional Functions
11 July 2015
H. Lundbeck A/S
FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia
6 May 2015
H. Lundbeck A/S
Kåre Schultz appointed new president and CEO of Lundbeck
17 December 2014
H. Lundbeck A/S
Lundbeck discontinues further development of desmoteplase; 2014 profit guidance range narrowed
7 December 2014
H. Lundbeck A/S
US FDA approves the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia
24 November 2014
H. Lundbeck A/S
Ulf Wiinberg resigns as CEO of Lundbeck
3 November 2014
H. Lundbeck A/S
Aripiprazole once-monthly shows superior effectiveness to paliperidone palmitate once-monthly on quality of life scale in patients with schizophrenia